Merkel Cell Carcinoma
95
19
39
25
Key Insights
Highlights
Success Rate
58% trial completion
Published Results
16 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
18.9%
18 terminated out of 95 trials
58.1%
-28.4% vs benchmark
3%
3 trials in Phase 3/4
64%
16 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 25 completed trials
Clinical Trials (95)
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
A Study of CRD3874-SI in People With Solid Tumors
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
French National Database of Rare Dermatological Cancers
DOTATOC PET/CT for Imaging NET Patients
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies